Heartland Bank & Trust Co Purchases New Stake in DaVita Inc. (NYSE:DVA)

Heartland Bank & Trust Co bought a new position in shares of DaVita Inc. (NYSE:DVA - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,305 shares of the company's stock, valued at approximately $353,000.

Several other hedge funds have also recently added to or reduced their stakes in DVA. UMB Bank n.a. lifted its position in DaVita by 65.5% in the first quarter. UMB Bank n.a. now owns 192 shares of the company's stock valued at $29,000 after acquiring an additional 76 shares during the last quarter. Copia Wealth Management purchased a new stake in DaVita in the 4th quarter valued at $30,000. SBI Securities Co. Ltd. purchased a new position in shares of DaVita during the fourth quarter worth about $41,000. Coppell Advisory Solutions LLC lifted its stake in shares of DaVita by 50.0% in the 4th quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company's stock worth $45,000 after acquiring an additional 100 shares during the period. Finally, Canada Post Corp Registered Pension Plan purchased a new stake in shares of DaVita during the 4th quarter worth $55,000. Institutional investors and hedge funds own 90.12% of the company's stock.

DaVita Trading Up 0.4%

DaVita stock traded up $0.59 during trading on Thursday, reaching $140.95. The company had a trading volume of 949,260 shares, compared to its average volume of 804,289. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.20 and a current ratio of 1.25. The firm has a market capitalization of $10.64 billion, a price-to-earnings ratio of 13.97, a PEG ratio of 0.97 and a beta of 1.11. DaVita Inc. has a 12-month low of $131.76 and a 12-month high of $179.60. The stock's 50 day moving average price is $139.43 and its two-hundred day moving average price is $149.61.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported $2.00 EPS for the quarter, beating the consensus estimate of $1.75 by $0.25. DaVita had a net margin of 6.63% and a return on equity of 176.11%. The firm had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.22 billion. During the same quarter last year, the firm posted $2.26 earnings per share. DaVita's revenue for the quarter was up 5.0% compared to the same quarter last year. As a group, equities analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on DVA. Truist Financial reduced their price objective on shares of DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a research note on Monday, May 19th. Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $164.50.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.